成人免费看AA片,18以下勿进色禁网站永久,2020亚洲А∨天堂在线直播

EN| News Releases
News Releases

News Releases

Home>News Releases
China Resources Pharmaceutical Ranks No.2 of Top 10 China Enterprises in the PRC Pharmaceutical Industry Again

Press time:2016-11-18From:CR Pharma [Font:BigMediumSmall]

The “China ChemPharm Annual Summit 2016” which jointly organized by China Pharmaceutical Industry Association, China Association of Pharmaceutical Commerce, China Nonprescription Medicines Association and China Pharmaceutical Enterprises Development Promote Association was held in Wuhan, China on November 15th,2016. The “Excellent enterprises and brands in the PRC Chemical Pharmaceutical Industry of 2016” was released during the summit. China Resources Pharmaceutical (“CR Pharma”) ranks 2nd on “Top 10 China Enterprises in the PRC Chemical Pharmaceutical Industry of 2016” listing.

CR Pharma’s subsidiaries, including CR Double-Crane, CR Zizhu and CR Saike were all listed on the “Top 100 Enterprises in the PRC Chemical Pharmaceutical Industry of 2016”, which ranks 21st, 73rd and 79th respectively. “Compound Dexamethasone Acetate Cream (Pi Yan Ping)” from CR Sanjiu continually won the “Excellent OTC brand in PRC Chemical Pharmaceutical Industry” award. At the same time, “Pitavastatin Calcium Tablets (Guan Shuang)”, “Levofloxacin” ,“Sodium Chloride Injection (Ying Yuan)”, “ Gliquidone” and basic injection products from CR Double-Crane, “Amlodipine Besylate Tablets (Ya Shi Da)” and “Valsartan Capsules (Hui Yue)” from CR Saike, “Levonorgestrel  Tablets (Yu Ting)” and “Jin Yuting” from CR Zizhu won the awards of “Excellent Brand”.

The theme of the summit this year was “Quality, Integrity and Brand”. The summit was a great opportunities for deep communication between Chemical Pharmaceutical enterprises in terms of understanding national relevant policies, analyzing pharmaceutical economic trend and publishing construction of drug traceability system, credit evaluation of pharmaceutical enterprises and etc.

CR Pharma will continue to pursue strategic acquisitions and to focus on research and innovation to further upgrade core competitiveness, to consolidate the leadership positions in the pharmaceutical industry and to provide high quality products and high value services to customers.

Back to Top

  • <menuitem id="bgbmp"><rp id="bgbmp"><em id="bgbmp"></em></rp></menuitem>

    <form id="bgbmp"></form>
  • <strong id="bgbmp"><strong id="bgbmp"><object id="bgbmp"></object></strong></strong>

    主站蜘蛛池模板: 姜堰市| 托克托县| 临武县| 鄂温| 五大连池市| 马公市| 石阡县| 奉化市| 西吉县| 桂阳县| 万州区| 盐亭县| 廉江市| 梅河口市| 靖边县| 缙云县| 洞头县| 静安区| 兴文县| 杂多县| 垣曲县| 疏附县| 明水县| 海丰县| 临颍县| 崇明县| 大洼县| 晋城| 宜兴市| 茂名市| 承德市| 东安县| 渝北区| 许昌市| 察隅县| 浙江省| 斗六市| 张家口市| 芦溪县| 鲁山县| 麻阳|